PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-6.68
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
No Data
No Data available this quarter, please select a different quarter.
5.00
P/B 50-75% of AGEN's 7.39. Bruce Berkowitz would examine if asset composition explains the gap.
-14.13
Negative FCF while AGEN shows P/FCF of 115.08. Joel Greenblatt would examine cash flow improvement potential.
-14.13
Negative operating cash flow while AGEN shows P/OCF of 103.78. Joel Greenblatt would examine operational improvement potential.
5.00
Fair value ratio 50-75% of AGEN's 7.39. Bruce Berkowitz would examine if business quality explains the gap.
-3.74%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-7.08%
Negative FCF while AGEN shows yield of 0.87%. Joel Greenblatt would examine cash flow improvement potential.